OncoCyte (NASDAQ:OCX) Research Coverage Started at StockNews.com

Posted by Defense World Staff on Jul 17th, 2024

Equities researchers at StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX – Get Free Report) in a research report issued to clients and investors on Wednesday. The firm set a “sell” rating on the stock.

A number of other analysts have also recently issued reports on the company. Benchmark reiterated a “speculative buy” rating and set a $5.00 target price on shares of OncoCyte in a report on Monday, April 15th. Stephens restated an “equal weight” rating and issued a $4.00 target price on shares of OncoCyte in a research note on Wednesday, April 17th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $4.25 target price on shares of OncoCyte in a research note on Thursday, May 16th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $4.06.

Get Our Latest Research Report on OCX

OncoCyte Price Performance

Shares of OCX opened at $3.29 on Wednesday. OncoCyte has a 1-year low of $2.08 and a 1-year high of $4.64. The firm has a fifty day moving average price of $2.86 and a 200 day moving average price of $2.93.

OncoCyte (NASDAQ:OCX – Get Free Report) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($1.13) EPS for the quarter. OncoCyte had a negative return on equity of 135.45% and a negative net margin of 2,905.14%. The company had revenue of $0.18 million for the quarter. As a group, equities analysts expect that OncoCyte will post -2.58 EPS for the current fiscal year.

About OncoCyte

(Get Free Report)

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.

Receive News & Ratings for OncoCyte Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for OncoCyte and related companies with MarketBeat.com’s FREE daily email newsletter.